Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04783389 · ClinicalTrials.gov registry record · Phase 2
A Study to Evaluate CBP-201, Rademikibart, in Adult Patients With Chronic Rhinosinusitis With Nasal Polyps
A Phase 2 study, sponsored by Connect Biopharm.
- Terminated
- Registry status
- Phase 2
- Development phase
- 40
- Enrollment target
NCT04783389 is a Phase 2 study that was terminated before completion, run by Connect Biopharm. The registered enrollment target is 40 participants.
The verdict
NCT04783389, a Phase 2 study, was terminated before completion, sponsored by Connect Biopharm.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 40 participants
- Enrollment target
Study Summary
This study will evaluate the effect of CBP-201, rademikibart, in adult patients with Chronic Rhinosinusitis with Nasal Polyps (CRSwNP).
Interventions
- DRUG Placebo
- DRUG CBP-201
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2021-06-16 |
| Est. Completion | 2022-06-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04783389
The ClinicalTrials.gov registry entry for NCT04783389 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Connect Biopharm, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04783389 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04783389 about?
NCT04783389 is a clinical study titled "A Study to Evaluate CBP-201, Rademikibart, in Adult Patients With Chronic Rhinosinusitis With Nasal Polyps". This study will evaluate the effect of CBP-201, rademikibart, in adult patients with Chronic Rhinosinusitis with Nasal Polyps (CRSwNP).
What is the current status of trial NCT04783389?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 40 participants. The study started on 2021-06-16. Estimated completion is 2022-06-10.
What interventions are being tested in trial NCT04783389?
The interventions under investigation include: Placebo (DRUG), CBP-201 (DRUG).
Who is sponsoring clinical trial NCT04783389?
This trial is sponsored by Connect Biopharm, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.